The association of sexual dysfunction with race in women with gynecologic malignancies
Gynecologic cancer survivors report sexual health among their highest concerns. The aim of this study was to identify the prevalence of sexual dysfunction (SD) in survivors of gynecologic malignancies and to evaluate the association of sexual function with race, ethnicity and treatment modality. In...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-11-01
|
Series: | Gynecologic Oncology Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578919300840 |
id |
doaj-d693b52c73704a878229cc5457eab46f |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
M. Frimer L.B. Turker V. Shankar R. Cardaci A.R. Van Arsdale E. Rosenthal D.Y.S. Kuo G.L. Goldberg N. Nevadunsky |
spellingShingle |
M. Frimer L.B. Turker V. Shankar R. Cardaci A.R. Van Arsdale E. Rosenthal D.Y.S. Kuo G.L. Goldberg N. Nevadunsky The association of sexual dysfunction with race in women with gynecologic malignancies Gynecologic Oncology Reports |
author_facet |
M. Frimer L.B. Turker V. Shankar R. Cardaci A.R. Van Arsdale E. Rosenthal D.Y.S. Kuo G.L. Goldberg N. Nevadunsky |
author_sort |
M. Frimer |
title |
The association of sexual dysfunction with race in women with gynecologic malignancies |
title_short |
The association of sexual dysfunction with race in women with gynecologic malignancies |
title_full |
The association of sexual dysfunction with race in women with gynecologic malignancies |
title_fullStr |
The association of sexual dysfunction with race in women with gynecologic malignancies |
title_full_unstemmed |
The association of sexual dysfunction with race in women with gynecologic malignancies |
title_sort |
association of sexual dysfunction with race in women with gynecologic malignancies |
publisher |
Elsevier |
series |
Gynecologic Oncology Reports |
issn |
2352-5789 |
publishDate |
2019-11-01 |
description |
Gynecologic cancer survivors report sexual health among their highest concerns. The aim of this study was to identify the prevalence of sexual dysfunction (SD) in survivors of gynecologic malignancies and to evaluate the association of sexual function with race, ethnicity and treatment modality. In this study, survivors of endometrial, cervical, vaginal, and vulvar cancer who presented to the gynecologic oncology practice were asked to self-administer the Female Sexual Function Index (FSFI) survey to evaluate their sexual function. The prevalence of SD was estimated and its association with demographic and clinical co-variates was analyzed. Of the 155 participants, the prevalence of SD was 44.5% (95%CI: 36.7–52.7). Patients were significantly more likely to report SD if they did not currently have a partner (69% vs 22% p < .01). Abstinence within six months of their cancer diagnosis was also associated with SD (72% vs 26% p < .01). Patients who self-identified as black race compared to white race were three times more likely to have SD (OR = 3.9, 95% CI 1.1–14.3). Patients who received adjuvant chemotherapy and radiation therapy compared to those who did not among the entire cohort had an increased risk of SD (OR = 3.4, 95% CI 1.2–9.6). In our diverse population, almost half of our patients were identified to have SD. Black as compared to white race reported significantly higher sexual dysfunction. An increased risk for sexual dysfunction was observed among those women who received chemotherapy and radiation with or without surgery. Precis: Survivorship is an important issue for women with gynecologic malignancies. This study addresses the high rates of sexual dysfunction in a racially diverse patient population. |
url |
http://www.sciencedirect.com/science/article/pii/S2352578919300840 |
work_keys_str_mv |
AT mfrimer theassociationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT lbturker theassociationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT vshankar theassociationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT rcardaci theassociationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT arvanarsdale theassociationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT erosenthal theassociationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT dyskuo theassociationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT glgoldberg theassociationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT nnevadunsky theassociationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT mfrimer associationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT lbturker associationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT vshankar associationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT rcardaci associationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT arvanarsdale associationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT erosenthal associationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT dyskuo associationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT glgoldberg associationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies AT nnevadunsky associationofsexualdysfunctionwithraceinwomenwithgynecologicmalignancies |
_version_ |
1725085795583262720 |
spelling |
doaj-d693b52c73704a878229cc5457eab46f2020-11-25T01:31:36ZengElsevierGynecologic Oncology Reports2352-57892019-11-0130The association of sexual dysfunction with race in women with gynecologic malignanciesM. Frimer0L.B. Turker1V. Shankar2R. Cardaci3A.R. Van Arsdale4E. Rosenthal5D.Y.S. Kuo6G.L. Goldberg7N. Nevadunsky8Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States of America; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Long Island, NY, United States of America; Corresponding author at: Zucker School of Medicine at Hofstra/Northwell, Long Island Jewish Medical Center, Department of Obstetrics and Gynecology, 270-05 76th Avenue, 2nd Floor New Hyde Park, NY 11040, United States of America.Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States of AmericaDepartment of Epidemiology & Population Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States of AmericaDepartment of Obstetrics and Gynecology, Jacobi Medical Center, Bronx, NY, United States of AmericaDivision of Gynecologic Oncology, Department of Obstetrics & Gynecology, and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States of AmericaDivision of Gynecologic Oncology, Department of Obstetrics & Gynecology, and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States of AmericaDivision of Gynecologic Oncology, Department of Obstetrics & Gynecology, and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States of America; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, United States of AmericaDivision of Gynecologic Oncology, Department of Obstetrics & Gynecology, and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States of America; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Long Island, NY, United States of AmericaDivision of Gynecologic Oncology, Department of Obstetrics & Gynecology, and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States of America; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, United States of AmericaGynecologic cancer survivors report sexual health among their highest concerns. The aim of this study was to identify the prevalence of sexual dysfunction (SD) in survivors of gynecologic malignancies and to evaluate the association of sexual function with race, ethnicity and treatment modality. In this study, survivors of endometrial, cervical, vaginal, and vulvar cancer who presented to the gynecologic oncology practice were asked to self-administer the Female Sexual Function Index (FSFI) survey to evaluate their sexual function. The prevalence of SD was estimated and its association with demographic and clinical co-variates was analyzed. Of the 155 participants, the prevalence of SD was 44.5% (95%CI: 36.7–52.7). Patients were significantly more likely to report SD if they did not currently have a partner (69% vs 22% p < .01). Abstinence within six months of their cancer diagnosis was also associated with SD (72% vs 26% p < .01). Patients who self-identified as black race compared to white race were three times more likely to have SD (OR = 3.9, 95% CI 1.1–14.3). Patients who received adjuvant chemotherapy and radiation therapy compared to those who did not among the entire cohort had an increased risk of SD (OR = 3.4, 95% CI 1.2–9.6). In our diverse population, almost half of our patients were identified to have SD. Black as compared to white race reported significantly higher sexual dysfunction. An increased risk for sexual dysfunction was observed among those women who received chemotherapy and radiation with or without surgery. Precis: Survivorship is an important issue for women with gynecologic malignancies. This study addresses the high rates of sexual dysfunction in a racially diverse patient population.http://www.sciencedirect.com/science/article/pii/S2352578919300840 |